<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03126019</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 50465-203 (CITADEL-203)</org_study_id>
    <nct_id>NCT03126019</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)</brief_title>
  <official_title>A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the objective response rate of INCB050465 treatment in
      subjects with relapsed or refractory follicular lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate with INCB050465 based on Lugano classification response criteria</measure>
    <time_frame>Weeks 8, 16, and 24, and every 12 weeks thereafter until disease progression, up to approximately 12 months.</time_frame>
    <description>Defined as the percentage of subjects with a complete response (CR) or partial response (PR) as determined by an independent review committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate with INCB050465 based on Lugano classification response criteria</measure>
    <time_frame>Up to approximately 12 months per subject</time_frame>
    <description>Defined as the percentage of subjects with a CR as determined by an independent review committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to approximately 12 months per subject</time_frame>
    <description>Defined as the time from first documented evidence of CR or PR until disease progression or death from any cause among subjects who achieve an objective response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival with INCB050465</measure>
    <time_frame>Up to approximately 24 months per subject (approximately 12 months for median)</time_frame>
    <description>Defined as the time from the date of first dose of study treatment until the earliest date of disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival with INCB050465</measure>
    <time_frame>Up to approximately 36 months per subject</time_frame>
    <description>Defined as the time from the date of first dose of study treatment until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of INCB050465 measured by adverse events (AEs)</measure>
    <time_frame>Baseline through 30-35 days after end of treatment, up to approximately 12 months per subject</time_frame>
    <description>Defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB050465 once daily (QD) for 8 weeks followed by INCB050465 once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB050465 QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB050465</intervention_name>
    <description>INCB050465 at the protocol-defined starting dose for 8 weeks, followed by INCB050465 at the protocol-defined dose QD</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB050465</intervention_name>
    <description>INCB050465 at the protocol-defined starting dose for 8 weeks, followed by INCB050465 at the protocol-defined dose once weekly</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older.

          -  Histologically confirmed, relapsed or refractory, follicular B-cell NHL (follicular
             lymphoma) Grade 1, 2, and 3a.

          -  Ineligible for hematopoietic stem cell transplant.

          -  Must have been treated with at least 2 prior systemic therapies.

          -  Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined
             as the presence of ≥ 1 lesion that measures &gt; 1.5 cm in the longest dimension and ≥
             1.0 cm in the longest perpendicular dimension as assessed by computed tomography or
             magnetic resonance imaging.

          -  Must be willing to undergo an incisional, excisional, or core needle lymph node or
             tissue biopsy or provide a lymph node or tissue biopsy from the most recent available
             archival tissue.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

        Exclusion Criteria:

          -  Known histological transformation from indolent NHL to diffuse large B-cell lymphoma.

          -  History of central nervous system lymphoma (either primary or metastatic).

          -  Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-PI3K
             inhibitor.

          -  Prior treatment with a Bruton's tyrosine kinase inhibitor (eg, ibrutinib).

          -  Allogeneic stem cell transplant within the last 6 months, or autologous stem cell
             transplant within the last 3 months before the date of study treatment administration.

          -  Active graft-versus-host disease.

          -  Subjects positive for hepatitis B surface antigen or hepatitis B core antibody will be
             eligible if they are negative for HBV-DNA. Subjects positive for anti-HCV antibody
             will be eligible if they are negative for HCV-RNA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Corrado, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Oncology Associates - Biltmore Cancer Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>602-277-4868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-600-6126</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-521-3830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Institute of Research (Innovative Clinical Research Institute)</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>562-693-4477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Central Connecticut</name>
      <address>
        <city>Plainville</city>
        <state>Connecticut</state>
        <zip>06062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>860-224-4408</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>941-957-1000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of SWLA, LLC</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>337-602-6642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-576-8673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>601-261-1700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>816-932-2881</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas City Veterans Affairs Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>816-861-4700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance, Inc.</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>516-488-2918</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-423-0632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>330-492-3345</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-614-1846</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates, PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-577-6957</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute: Tennessee Oncology, Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>615-986-7600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-703-2398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance (SCCA)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-288-2037</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follicular lymphoma</keyword>
  <keyword>non-Hodgkin lymphoma (NHL)</keyword>
  <keyword>phosphatidylinositol 3-kinase (PI3K) δ inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

